Skip to main content

Table 1 Baseline (pre-cART) clinical and laboratory characteristics by incident neuropathic symptom status

From: Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study

   Nested case (neuropathic symptoms) vs control (symptom-free) sample
Variable Total cohort remaining symptom-free N = 88 Neuropathic symptom group N = 30 Control group N = 30 Total N = 60
Female sex, N (%) 62 (70) 22 (73) 22 (73) 44 (73)
Age *, years 31 (27 – 38) 32 (26 - 35) 34 (26 - 41) 33 (26 - 37)
Weight *, kg 63 (56- 72) 58.0 (52.5 - 68.5) 59.5 (54.0 - 64.0) 58.5 (53.0 - 68.0)
Height *, m 1.61 (1.56 - 1.69) 1.58 (1.55 - 1.64) 1.62 (1.57 - 1.65) 1.61 (1.55 - 1.64)
Body Mass Index *, kg/m2 23.3 (20.3 - 28.0) 22.7 (20.1 - 28.0) 22.6 (19.8 - 25.3) 22.6 (19.8 - 28.0)
dNRTI , N (%) 68 (77) 24 (40) 22 (37) 46 (77)
D4T/3TC/NNRTI 68 (77) 24 (40) 22 (37) 46 (77)
AZT/3TC/NNRTI 5 (6) 2 (7) 3 (10) 5 (8)
TDF/3TC/NNRTI 15 (17) 4 (13) 5 (17) 9 (15)
Previous TB, N (%) 25 (28) 7 (23) 7 (23) 14 (23)
< 1 year ago 13 (15) 3 (10) 3 (10) 6 (10)
1 year ago 1 (1) 0 (0) 0 (0) 0 (0)
2 years ago 2 (2) 0 (0) 1 (3) 1 (2)
> 2 years ago 9 (10) 4 (13) 3 (10) 7 (12)
Years since HIV diagnosis * 1 (1-3.4) 1 (1-3.5) 2 (1-4) 1 (1-3.8)
WHO stage, N (%)     
Stage 1 30 (34) 6 (20) 12 (40) 18 (30)
Stage 2 25 (28) 18 (60) 10 (33) 28 (47)
Stage 3 30 (34) 5 (17) 7 (23) 12 (20)
Stage 4 3 (3) 1 (3) 1 (3) 2 (3)
White cell count *, ×109/L 5.1 (4.0 - 6.6) 5.7 (3.9 - 6.4) 5.7 (4.4 - 7.9) 5.7 (4.3 - 7.1)
CD4 T-cell count *, cells/mm3 163 (125 - 193) 145 (109 - 181) 138 (110 - 194) 141 (110 - 189)
CD4 T-cell count, N (%)     
< 100 cells/mm 3 15 (17) 5 (17) 6 (20) 11 (18)
100 - 200 cells/mm 3 56 (64) 19 (63) 20 (67) 39 (65)
> 200 cells/mm 3 17 (19) 6 (20) 4 (13) 10 (17)
hs-CRP *, mg/L 2.6 (0.9 - 6.5) 2.6 (0.9 - 5.4) 2.9 (0.9 - 6.7) 2.7 (0.9 - 6.7)
  1. The total cohort remaining symptom-free refers to individuals who were asymptomtic at baseline and remained free of neuropathic symptoms in the first 6 months of starting cART; the nested control group were extracted from this total cohort and paired (with the neuropathic symptom group) for previously identified risk factors. The neuropathic symptom group refers to individuals developing symptoms within 12 weeks of starting cART.
  2. Abbreviations: dNRTI dideoxy-nucleoside reverse-transcriptase inhibitor (d-drug), D4T stavudine, 3TC lamivudine, AZT zidovudine, TDF tenofovir, TB tuberculosis, WHO World Health Organization, hs-CRP high-sensitivity C-reactive protein.
  3. *Median (Interquartile range).
  4. dNRTI refers to d-drug containing combination antiretroviral therapy regimen commenced subsequent to baseline assessment. NNRTI refers to non-nucleoside reverse transcriptase inhibitor and were either efavirenz or nevirapine.